Cynosure also assumed certain contractual and current liabilities associated with normal working capital.

US-based Ellman develops advanced radiofrequency (RF) technology for precision surgical and aesthetic procedures, as well as provides a line of aesthetic lasers.

Cynosure chairman and CEO Michael Davin said the transaction complements brand portfolio, expands market opportunities and enhances recurring revenue stream.

"The efficacy of products such as Ellman’s versatile Surgitron radiowave platform technology is supported by clinical validation in more than 300 surgical publications," Davin added.

Ellman’s product line includes multiple RF generators and single-use electrodes for aesthetic and multi-specialty surgical indications such as facial plastic and general surgery, gynecology, ear, nose and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology.

Ellman also produces RF-based Pelleve Wrinkle Reduction System, which is a skin tightening system for non-ablative skin rejuvenation.

Under the Cynosure, Palomar and ConBio brand names, Cynosure markets its products in the US, Canada, Mexico, France, Germany, Spain, the UK, Australia, China, Japan and Korea.